SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Lithium Americas Corp. engages in the development of the Thacker Pass project. It is focused on advancing Thacker Pass to production it is located in northern Nevada. The company was founded on January 23, 2023 and is headquartered in Vancouver, Canada.

Lithium Americas Corp (NewCo)

Lithium Americas Corp

Lithium Americas ($LAC) is trending as the Trump administration reportedly explores taking a stake in the company, potentially impacting its $2.26 billion Energy Department loan for the Thacker Pass lithium project. Community discussions revolve around the significance of government interest, comparing it to similar situations with $MP and $INTC, while also considering a recent downgrade from TD Cowen.

Fusion Fuel Green Plc engages in the research and development of solar technologies. It develops a process and technology to produce emission-free green hydrogen using concentrated photovoltaic technology. The company was founded in 2018 and is headquartered in Dublin, Ireland.

Fusion Fuel Green Ltd - Ordinary Shares - Class A

Fusion Fuel Green PLC

HTOO is trending due to news of a non-binding term sheet for hydrogen infrastructure investments, sparking discussions about the company's potential growth in the green energy sector. Community members are actively debating the significance of the deal, with some expressing skepticism based on past performance, while others are focusing on the stock's low float and potential for a squeeze. The conversation also includes the company's NASDAQ compliance status.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

AMZN is trending as investors discuss its self-driving unit Zoox seeking approval for autonomous vehicle deployment. Bullish sentiment is fueled by analyst upgrades and anticipation for Amazon's upcoming tech event, with some expecting a significant rally. However, concerns remain about retail margins and competition in the cloud and AI sectors.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Conversations around DJT are currently dominated by politically charged debates, with discussions ranging from free speech and media bias to immigration policies and accusations of violence incitement. The stock is also being discussed in the context of broader economic issues, such as tariffs, government shutdowns, and international relations. Community members are actively engaging in heated exchanges, often resorting to name-calling and the sharing of divisive content.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is trending due to promising trial data for its Huntington's disease gene therapy, showing significant slowing of disease progression. Despite positive efficacy signals, the community is discussing concerns about a recent public offering and potential dilution. The stock's movement is also influenced by broader biotech sector momentum, with some comparing it to other high-flying gene therapy stocks.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending as the crypto market experiences volatility, with community members debating potential bottom levels and the impact of external factors like a possible government shutdown. Discussions also include the influence of market manipulators and the potential for a significant rally in October. Bullish sentiment persists among some, who view the current prices as a buying opportunity before a predicted surge.

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Immuneering Corp - Ordinary Shares Class A

IMRX is trending due to positive clinical trial results for its pancreatic cancer treatment, showing significant overall survival rates. However, the stock experiences volatility as the company announced a public offering and concurrent private placement, raising concerns about potential dilution among investors. The community is actively debating the implications of the offering and its impact on the stock's future performance, especially with Sanofi's investment.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz is trending due to positive earnings reports and discussions around its strategic partnership with Amazon to sell used vehicles, sparking optimism about increased visibility and profitability. Community members are actively debating the potential for a short squeeze given the stock's high short interest and comparing it to Carvana's market position, with some speculating about future partnerships.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X ($CCCX) is trending as investors discuss its merger with Infleqtion, a quantum computing company, and its potential to rival sector leaders. The community is highlighting Infleqtion's existing contracts, partnerships with companies like NVIDIA, and comparatively lower valuation, suggesting significant upside potential. Some are also discussing the warrants, viewing them as undervalued.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is trending as the community discusses its valuation relative to competitors, highlighting strong revenue growth and profitability while questioning market manipulation and short interest. Some are speculating on a potential buyout and anticipating positive news regarding pediatric approval and pipeline developments. Community members express frustration with the stock's price action despite positive earnings reports.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lucid Group (LCID) received a price target hike from Cantor Fitzgerald on Wednesday, following the company's announcement that it has delivered the first robotaxi engineering vehicle to California-based robotics company Nuro.Lucid <a href="https://stocktwits.com/news-articles/markets/equity/uber-to-deploy-lucid-gravity-suvs-as-robotaxi-on-platform/ch8KVdIR5pR">announced</a> in July that Uber Technologies (UBER) plans to deploy 20,000 or more of its vehicles on the Uber platform as robotaxis. Uber will deploy the Lucid vehicles over six years, equipped with startup Nuro, Inc.’s Level 4 autonomy system, called Nuro Driver, the company said.On Wednesday, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/LucidMotors/status/1970836212358525405">said</a> in a post on X that it has delivered the first vehicle to Nuro for the installation of a Nuro driver. Nuro's Level 4 self-driving system combines automotive-grade hardware and AI-powered self-driving software. The company had said that while the necessary hardware will be integrated into the Lucid Gravity SUV on its assembly line, it will receive Nuro's software only when Uber commissions the vehicle.<figure class="image"><img style="aspect-ratio:533/520;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_24_at_2_39_40_PM_png_71a911a829.webp" alt="Screenshot of Lucid's X Post" width="533" height="520"><figcaption>Screenshot of Lucid's X Post</figcaption></figure>Shares of the company rose 4% at the time of writing. On Stocktwits, retail sentiment around LCID stock fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:574/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_24_at_2_15_38_PM_png_7d67712a15.webp" alt="LCID's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Sept. 24, 2025 | Source: Stocktwits" width="574" height="62"><figcaption>LCID's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Sept. 24, 2025 | Source: Stocktwits</figcaption></figure>Cantor Fitzgerald subsequently raised the firm's price target on Lucid Group to $26 from $20, while maintaining a ‘Neutral’ rating on the shares, according to TheFly. The new price target implies an upside of about 17% from the stock’s closing price on Tuesday.Lucid can continue to pursue additional robotaxi opportunities for its Air or Midsize platform, as well as for other variants of Gravity, Cantor said. The analyst also expects Lucid to continue ramping up autonomy features in its vehicles to enhance their offering for customers, the analyst said.LCID stock is down 24% this year and approximately 35% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/harmony-biosciences-stock-slumps-after-rare-genetic-disorder-drug-fails-late-stage-study/chD1BhBR3Ed">Harmony Biosciences Stock Slumps After Rare Genetic Disorder Drug Fails Late-Stage Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

People sit inside a Lucid Gravity SUV at the New York International Auto Show on April 16, 2025 in New York City. (Photo by Adam Gray/Getty Images)

Lucid Stock Rises After Delivering Robotaxi Vehicle To Nuro For Deployment Into Uber Fleet: Check Out Cantor Fitzgerald’s New Price Target

The analyst’s new target of $26 implies an upside of about 17% from the stock’s closing price on Tuesday.

Equity

The analyst’s new target of $26 implies an upside of about 17% from the stock’s closing price on Tuesday.


Harmony Biosciences Holdings (HRMY) on Wednesday said that its late-stage study of ZYN002 in Fragile X syndrome did not meet the primary endpoint of improvement in social avoidance.Fragile X syndrome (FXS) is a rare genetic disorder that negatively affects synaptic function, plasticity, and neuronal connections. It results in a spectrum of intellectual disabilities and behavioral symptoms, such as social avoidance and irritability. According to the company, the disease affects upwards of 80,000 patients in the U.S. and 121,000 patients in the European Union and the U.K. The disease is more common in males than females, but there are no FDA-approved treatments for the disorder.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.harmonybiosciences.com/news-releases/news-release-details/harmony-biosciences-provides-update-its-phase-3-reconnect-study">said</a> on Wednesday that its drug did not meet the primary endpoint of the trial primarily due to a higher-than-expected placebo response rate.Shares of HRMY traded 15% lower at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HRMY">HRMY stock</a> rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:575/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_24_at_1_01_23_PM_png_17fb739829.webp" alt="HRMY's Sentiment Meter and Message Volume as of 1:01 p.m. ET on Sept. 24, 2025 | Source: Stocktwits" width="575" height="62"><figcaption>HRMY's Sentiment Meter and Message Volume as of 1:01 p.m. ET on Sept. 24, 2025 | Source: Stocktwits</figcaption></figure>Chief Medical Officer Kumar Budur stated that, although the study's findings did not meet the primary endpoint, they provide valuable insights into Fragile X syndrome. “We will conduct a comprehensive analysis of the full dataset to better understand the results as part of our continued commitment to the Fragile X community,” Budur said.The trial, which enrolled 215 patients with FXS aged 3 to under 30 years, aimed to assess the efficacy and safety of ZYN002, a pharmaceutically manufactured synthetic cannabidiol.CEO Jeffrey M. Dayno stated that the company has additional candidates in its pipeline. “We have a late-stage, catalyst-rich pipeline with multiple Phase 3 programs in the clinic and continue to be on track to initiate our Phase 3 trials for pitolisant HD in narcolepsy and idiopathic hypersomnia in the fourth quarter of this year,” he said.HRMY stock is down by 21% this year and by 28% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/honda-motor-reportedly-ends-us-production-of-acura-zdx-ev/chD14gFR33x">Honda Motor Reportedly Ends US Production Of Acura ZDX EV</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Harmony Biosciences Stock Slumps After Rare Genetic Disorder Drug Fails Late-Stage Study

The company said on Wednesday that its drug did not meet the primary endpoint of the trial primarily due to a higher-than-expected placebo response rate.

TNF Pharmaceuticals, Inc. (TNFA) announced on Wednesday that it has changed its corporate name to Q/C Technologies and will begin trading under a new ticker on the Nasdaq Capital Market starting Thursday.TNF Pharmaceuticals stated that no action is required from current shareholders regarding the name change. The firm <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tnfpharma.com/news-events/press-releases/detail/81/tnf-pharmaceuticals-announces-name-change-to-qc">noted</a> that the new name represents the company’s recent strategic pivot into quantum-class computing. The company has exclusive global rights to LightSolver’s light-speed laser processing unit (LPU), a light and laser-based computing system for application in the cryptocurrency vertical.LPUs can reduce energy consumption by up to 90% while outperforming traditional GPUs and quantum computing in both speed and efficiency, the company said. Lighsolver’s architecture is further designed to improve security for blockchain operations and is expected to position the company at the forefront of innovation in blockchain infrastructure, the company said.Following the announcement, <a href="https://stocktwits.com/symbol/TNFA">TNFA shares</a> surged by about 101% by the afternoon of Wednesday. On Stocktwits, retail sentiment around TNFA jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘extremely low’ to ‘high’ levels. The stock will begin trading under the new ticker symbol QCLS starting Thursday, September 25.The company added that it also continues to evaluate strategic options for its therapeutic programs, Isomyosamine and Supera-CBD. While Isomyosamine has potential for the treatment of chronic inflammation, Supera-CBD holds potential in managing addiction. The company is looking to realize maximum value from these assets as it undertakes the pivot into computing and blockchain infrastructure.TNFA stock is down by 94% this year.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/harmony-biosciences-stock-slumps-after-rare-genetic-disorder-drug-fails-late-stage-study/chD1BhBR3Ed">Harmony Biosciences Stock Slumps After Rare Genetic Disorder Drug Fails Late-Stage Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

TNF Pharmaceuticals Stock More Than Doubles After Announcing Name Change To Represent Pivot Into Quantum-Class Computing

The company holds exclusive global rights to LightSolver’s light-speed laser processing unit (LPU), a light and laser-based computing system designed for use in the cryptocurrency sector.

TNF Pharmaceuticals Stock Nearly Doubles After Announcing Name Change To Represent Pivot Into Quantum-Class Computing

The company holds exclusive global rights to LightSolver’s light-speed laser processing unit (LPU), a light and laser-based computing system designed for use in the cryptocurrency sector.


Honda Motor Co. (HMC) is reportedly ending the U.S. production of its Acura ZDX electric crossover, which was produced by General Motors (GM) at its Spring Hill Assembly plant.CNBC <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/09/24/honda-acura-ev-gm.html">reported</a> on Wednesday, citing a message to plant workers, that the company has decided to cancel all future production of the vehicle at the Tennessee facility. A Honda spokeswoman also confirmed the plans to CNBC, citing market conditions for EVs as the reason behind the decision. Production of the 2026 model year of the vehicle was expected to begin this month.<a href="https://stocktwits.com/symbol/HMC">HMC shares</a> traded 1.5% lower at the time of writing. On Stocktwits, retail sentiment around HMC stayed within the ‘bullish’ territory while message volume stayed at ‘normal’ levels.The Honda spokeswoman told CNBC that the production of the Honda Prologue EV by GM will continue in Mexico. “To better align our product portfolio with the needs of our customers and market conditions, as well as our long-term strategic goals, we can confirm the Acura ZDX has ended production,” she told CNBC in a statement. She added that the ZDX will provide a foundation for the electric Acura RSX slated to be produced at the EV Hub in Ohio in the second half of 2026.Since the vehicle’s release in the U.S. last year, the company has sold approximately 19,000 ZDX models, CNBC noted. According to the report, the message to plant workers said that the companies are aligning EV production to better match slower demand, and the decision to end Acura ZDX production has nothing to do with the relationship between the companies or the quality of products.“Honda’s decision isn’t a reflection on the capabilities of the Spring Hill workforce or GM’s commitment to Spring Hill,” the message read, as reported by CNBC. It also reportedly added that the vehicle shift does not change GM’s employment plans for the facility.HMC stock is up 17% this year and approximately 2% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/baidu-apollo-go-gets-dubais-first-autonomous-driving-test-permit-commences-on-road-trials/chD1EPjR33u">Baidu’s Apollo Go Gets Dubai's First Autonomous Driving Test Permit, Commences On-Road Trials</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Honda sign on building exterior along North Main Street, Walnut Creek, California, March 6, 2025. (Photo by Smith Collection/Gado/Getty Images)

Honda Motor Reportedly Ends US Production Of Acura ZDX EV

The vehicle was produced by General Motors at its Spring Hill Assembly plant. 

China-based Baidu (BIDU) announced on Wednesday that its autonomous ride-hailing platform, Apollo Go, has commenced trials in designated areas on open roads in Dubai since August, sending the Nasdaq-listed company's shares rallying 7%.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/baidus-apollo-go-granted-dubais-first-batch-of-autonomous-driving-test-licenses-conducts-on-road-trials-in-urban-dubai-302565963.html#:~:text=Apollo%20Go%20has%20been%20granted,areas%20in%20Dubai%20since%20August">said</a> that Apollo Go has been granted Dubai's first autonomous driving trial permit, along with the first batch of 50 autonomous driving test licenses issued by the Roads and Transport Authority (RTA) of Dubai. The RTA thereby authorized Apollo Go to deploy its vehicles in urban Dubai."Leveraging our autonomous driving technologies and fleet operation expertise, we will conduct all required testing and operations to enable seamless localization,” said Liang Zhang, Managing Director of EMEA, Baidu Apollo.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BIDU">BIDU stock</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.Apollo Go is the first platform to be allowed to operate a sizable fleet in urban Dubai, the company said. Apollo Go and the RTA also plan to expand the fleet to over 1,000 fully driverless vehicles over the next three years, the firm stated.Apollo Go and Dubai RTA signed a Memorandum of Understanding earlier this year. The company said that Apollo Go is the sole platform running trials on open roads with sixth-generation autonomous vehicles at the 4th Dubai World Congress for self-driving transport. In Hong Kong, Apollo Go was granted the very first autonomous driving test license in November 2024BIDU stock is up by 60% this year and by 42% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/honda-motor-reportedly-ends-us-production-of-acura-zdx-ev/chD14gFR33x">Honda Motor Reportedly Ends US Production Of Acura ZDX EV</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Baidu's Apollo Go Robotaxi drives on the street on September 2, 2023 in Chongqing, China

Baidu’s Apollo Go Gets Dubai's First Autonomous Driving Test Permit, Commences On-Road Trials

Apollo Go and the RTA also plan to expand the fleet to over 1,000 fully driverless vehicles over the next three years, the firm stated.

Ford Motor Co. (F) is recalling 115,539 vehicles in the U.S. over concerns regarding loss of steering control, the National Highway Traffic Safety Administration (NHTSA) said on Wednesday.The recall includes certain model year 2020-2021 F-250, F-350, and F-450 trucks. <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://static.nhtsa.gov/odi/rcl/2025/RCLRPT-25V626-1284.pdf">According</a> to the regulator, the steering column’s upper shaft may detach from the column, resulting in a loss of steering control and an increased risk of a crash.As for a solution, dealers will inspect the steering column and repair or replace the upper shaft as necessary, it said. The customer will not be charged for the fix. The final remedy is expected to be available by December 2025, the regulator addedFord shares rose 0.3% on Wednesday morning at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/F">Ford</a> remained within the ‘bearish’ territory, while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:575/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_24_at_10_09_13_AM_png_3dd461500b.webp" alt="F's Sentiment Meter and Message Volume as of 10:09 a.m. ET on Sept. 24, 2025 | Source: Stocktwits" width="575" height="62"><figcaption>F's Sentiment Meter and Message Volume as of 10:09 a.m. ET on Sept. 24, 2025 | Source: Stocktwits</figcaption></figure>According to the NHTSA filing, Ford’s team reviewed supplier process and maintenance records to determine the recall population. The vehicles affected by the recall were built between Feb. 19, 2019, and Sept. 30, 2020, at the Kentucky Truck Plant.The regulator stated that Ford is aware of seven warranty claims, three field reports, and four customer call hotline reports, all of which are likely related to the concerns as of September 11. However, the company is not aware of any accidents or injuries related to the condition, it added.Ford stock is up approximately 19% this year and over 8% in the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/acadia-health-care-stock-surges-pre-market-after-activist-hedge-fund-reportedly-seeks-board-revamp/chD1bdjR33W">Acadia Healthcare Stock Surges After Activist Hedge Fund Reportedly Seeks Board Revamp</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ford logo seen on a car outside a Ford dealership in Edmonton, AB, Canada, on February 02, 2025. (Photo by Artur Widak/NurPhoto via Getty Images)

Ford Recalls Over 115,000 F-Series Trucks Due To Loss Of Steering Control Concerns

According to NHTSA, the steering column’s upper shaft may detach from the column, resulting in a loss of steering control and an increased risk of a crash. 

Incannex Healthcare Inc. (IXHL) has experienced a 234% increase in retail chatter on Stocktwits over the past seven days, while message volumes have risen 193% over the past 30 days on the platform. Shares of the company drew investor attention on Wednesday morning as it declined nearly 10% at the opening bell.Incannex is developing combination medicines for several chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalised anxiety disorder. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IXHL">IXHL stock</a> jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:574/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_24_at_9_16_43_AM_png_8958508111.webp" alt="IXHL's Sentiment Meter and Message Volume as of 9:17 a.m. ET on Sept. 24, 2025 | Source: Stocktwits" width="574" height="66"><figcaption>IXHL's Sentiment Meter and Message Volume as of 9:17 a.m. ET on Sept. 24, 2025 | Source: Stocktwits</figcaption></figure>Last month, the company <a href="https://stocktwits.com/news-articles/markets/equity/why-is-incannex-healthcare-surging-today/chsHHZBRdjh">announced </a>positive data from a mid-stage trial evaluating PSX-001 for Generalised Anxiety Disorder (GAD). The company stated that the trial results confirm statistically significant and clinically meaningful improvements across all key endpoints assessed, including the Hamilton Anxiety Rating Scale. The trial enrolled 73 adult participants diagnosed with moderate to severe Generalised Anxiety Disorder.PSX-001, also called Psi-GAD, is a psilocybin-assisted psychotherapy treatment. Patients treated with PSX-001 in the study achieved an average 12.8-point reduction in Hamilton Anxiety Rating Scale scores from baseline, compared to a 3.6-point decrease in the placebo group.Of patients receiving treatment, 27% achieved complete disease remission, which is five times higher than the placebo rate, the company said. Additionally, the firm is exploring strategic partnerships to accelerate development and broaden global access to PSX-001.The company’s other two clinical-stage product candidates, IHL-42X and IHL-675A, are in different stages of development. While IHL-42X has completed a mid-stage clinical trial in obstructive sleep apnoea, IHL-675A is currently in a mid-stage clinical development program for the treatment of inflammatory conditions such as Arthritis.Incannex also <a href="https://stocktwits.com/news-articles/markets/equity/incannex-stock-soars-after-board-authorizes-20-million-share-repurchase-program/chsZIp3RdK2">authorized</a> a $20 million share repurchase program in August. CEO Joel Latham had stated that the program reflects the company’s confidence in the strength of its pipelines and the opportunities ahead. “We believe the current market valuation does not accurately reflect the significant progress we have made across our clinical programs,” he said.A Stocktwits user, meanwhile, expressed hopes for a partnership or buyout announcement on the company’s next earnings announcement.<stembedurl>https://stocktwits.com/IKEGAI/message/629801176</stembedurl>Shares of the company slumped 71% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/acadia-health-care-stock-surges-pre-market-after-activist-hedge-fund-reportedly-seeks-board-revamp/chD1bdjR33W">Acadia Healthcare Stock Surges After Activist Hedge Fund Reportedly Seeks Board Revamp</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Incannex Healthcare Inc. logo is seen on a smartphone and in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Incannex Healthcare Stock Sees Retail Chatter Explode 234% Over Last Week

The company is developing combination medicines for several chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalised anxiety disorder.

Activist hedge fund Engine Capital is reportedly pushing Acadia Healthcare (ACHC) to refresh its board as it faces multiple federal investigations.According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/e96d221b-c275-4b3e-86aa-250f784d55dc">report</a> by The Financial Times, the fund holds a roughly 3% stake in Acadia and has written a letter to the company's board, requesting a review of its asset portfolio, improvements to its board of directors, and the halting of capital-intensive projects for new facilities.Acadia provides for-profit behavioral healthcare services. It is currently facing probes from the Department of Justice and Securities and Exchange Commission over allegations of holding patients against their will and falsifying insurance claims, the report noted.Shares of the company rose over 8% on Wednesday morning following the news. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ACHC">ACHC</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.Tennessee-headquartered Acadia operated a network of 274 behavioral healthcare facilities, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers, and outpatient clinics, with approximately 12,100 beds in 39 states and Puerto Rico as of the end of June. The company estimates that it serves more than 82,000 patients daily.As per FT, Engine Capital accused Acadia of maintaining a “growth at any cost” approach in its letter. It alleged that the approach has given rise to a bloated corporate structure and noted that a 2022 reorganisation left the company with an unwieldy management structure that has stifled the company’s turnaround.The firm also urged the company to add new directors with experience in behavioral health and capital allocation, while noting that the current board has no director with relevant operating experience. The hedge fund also encouraged the company to consider selling its assets and repurchasing shares.ACHC stock is down 40% this year and approximately 69% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uniqure-stock-rises-pre-market-after-investigational-huntingtons-disease-drug-slows-disease-in-trial/chD1GAOR33X">uniQure Stock Rises Pre-Market After Investigational Huntington’s Disease Drug Slows Disease In Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration an Acadia Healthcare logo is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Acadia Healthcare Stock Surges After Activist Hedge Fund Reportedly Seeks Board Revamp

According to a report by The Financial Times, the fund has written a letter to the company's board, requesting a review of its asset portfolio and improvements to its board.

According to a report by The Financial Times, the fund holds a roughly 3% stake in Acadia and has written a letter to the company's board, requesting a review of its asset portfolio, improvements to its board, and the halting of capital-intensive projects for new facilities.

uniQure N.V. (QURE) on Wednesday said that a high dose of its experimental gene therapy AMT-130 demonstrated a statistically significant slowing of disease progression in Huntington’s disease in an early-to-mid stage trial.Shares of the company rose a whopping 161% in the pre-market session at the time of writing.Huntington’s disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms including chorea, behavioral abnormalities, and cognitive decline. The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.uniqure.com/investors-media/press-releases">stated</a> that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale (cUHDRS), a comprehensive assessment tool used in clinical trials for Huntington's disease. The company also identified a statistically significant 60% slowing of disease progression as measured by Total Functional Capacity (TFC) at 36 months.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/QURE">QURE stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.uniQure on Wednesday said that the therapy was generally well-tolerated in the trial with a manageable safety profile. No new drug-related serious adverse events have been observed from December 2022 to the end of June 2025, it added.Chief Medical Officer Walid Abi-Saab said that the company is looking forward to discussing the data with the U.S. Food and Drug Administration at a meeting later this year. The company plans to submit an application for approval of AMT-130 to the FDA in the first quarter of 2026 and anticipates launching it in the U.S. later in the same year.According to the company, there are currently no approved therapies to slow the progression of Huntington’s disease. The disease affects approximately 75,000 people in the U.S., EU, and the U.K., it added.QURE stock is down by 23% this year but has risen approximately 166% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/acadia-pharmaceuticals-investigational-drug-for-rare-genetic-disorder-fails-in-late-stage-study/chD1Gf0R33B">Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

QURE Stock Jumped A Whopping 161% Pre-Market – Here’s What Happened

The company stated that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale. 

Acadia Pharmaceuticals Inc. (ACAD) announced on Tuesday that its late-stage intranasal Carbetocin trial in Prader-Willi syndrome (PWS) patients did not achieve a statistically significant improvement in hyperphagia.The <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-phase-3-compass-pws-trial">study</a> enrolled 175 children and adults aged five to 30 years with PWS, a rare genetic disorder characterized by an insatiable hunger or hyperphagia and a constant need for food, leading to obesity. However, intranasal Carbetocin did not demonstrate a statistically significant improvement over placebo to week 12 on the Hyperphagia Questionnaire for Clinical Trials, the company said.The firm noted that the safety and tolerability of intranasal Carbetocin were consistent with those observed in previous clinical trials, with a low rate of adverse events.Shares of the company tumbled 11% in the pre-market session. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ACAD">ACAD stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.Acadia’s Head of Research and Development, Elizabeth HZ Thompson, said that the company is “disappointed” by these findings. “We are committed to sharing a summary of the data in the future to ensure learning for the PWS community; however, given these results, we do not intend to investigate intranasal carbetocin any further,” Thompson added.CEO Catherine Owen Adams highlighted that the firm’s approved products are projected to generate over $1 billion in net sales in 2025 despite the disappointment with the trial. The company’s drugs for the treatment of Rett syndrome and for treating hallucinations and delusions associated with Parkinson’s disease psychosis are approved by the U.S. Food and Drug Administration.“Looking ahead, we anticipate seven Phase 2 or 3 study starts through 2026 and four data readouts by the end of 2027,” the CEO added.ACAD stock is up 29% this year and approximately 49% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-mp-materials-stock-rising-today/chD1R9FR330">Why Is MP Materials Stock Rising Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Acadia Pharmaceuticals company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study 

The company noted that the safety and tolerability of intranasal Carbetocin were consistent with those observed in previous clinical trials.